These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Congenital Myasthenic Syndrome Caused by DOK7 Mutation in a Quinquagenarian Male with Calf Hypertrophy. Gomathy SB; Das A; Garg A; Srivastava AK J Clin Neuromuscul Dis; 2023 Sep; 25(1):51-54. PubMed ID: 37611271 [TBL] [Abstract][Full Text] [Related]
30. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia. Webster RG; Vanhaesebrouck AE; Maxwell SE; Cossins JA; Liu W; Ueta R; Yamanashi Y; Beeson DMW Hum Mol Genet; 2020 Aug; 29(14):2325-2336. PubMed ID: 32543656 [TBL] [Abstract][Full Text] [Related]
31. A late-onset congenital myasthenic syndrome due to a heterozygous DOK7 mutation. Bastos P; Barbosa R; Fernandes M; Alonso I Neuromuscul Disord; 2020 Apr; 30(4):331-335. PubMed ID: 32360404 [TBL] [Abstract][Full Text] [Related]
32. Congenital myasthenic syndrome due to choline acetyltransferase mutations in infants: clinical suspicion and comprehensive electrophysiological assessment are important for early diagnosis. Dilena R; Abicht A; Sergi P; Comi GP; Di Fonzo A; Chidini G; Natacci F; Barbieri S; Lochmüller H J Child Neurol; 2014 Mar; 29(3):389-93. PubMed ID: 23292760 [TBL] [Abstract][Full Text] [Related]
33. [Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy]. Nishikawa A; Mori-Yoshimura M; Okamoto T; Oya Y; Nakata T; Ohno K; Murata M Rinsho Shinkeigaku; 2014; 54(7):561-4. PubMed ID: 25087557 [TBL] [Abstract][Full Text] [Related]
34. Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up. Durmus H; Shen XM; Serdaroglu-Oflazer P; Kara B; Parman-Gulsen Y; Ozdemir C; Brengman J; Deymeer F; Engel AG Neuromuscul Disord; 2018 Apr; 28(4):315-322. PubMed ID: 29395675 [TBL] [Abstract][Full Text] [Related]
35. Successful treatment of congenital myasthenic syndrome caused by a novel compound heterozygous variant in RAPSN. Saito M; Ogasawara M; Inaba Y; Osawa Y; Nishioka M; Yamauchi S; Atsumi K; Takeuchi S; Imai K; Motobayashi M; Misawa Y; Iida A; Nishino I Brain Dev; 2022 Jan; 44(1):50-55. PubMed ID: 34565654 [TBL] [Abstract][Full Text] [Related]
36. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Burke G; Hiscock A; Klein A; Niks EH; Main M; Manzur AY; Ng J; de Vile C; Muntoni F; Beeson D; Robb S Neuromuscul Disord; 2013 Feb; 23(2):170-5. PubMed ID: 23219351 [TBL] [Abstract][Full Text] [Related]
37. Congenital myasthenic syndromes in adult neurology clinic: A long road to diagnosis and therapy. Kao JC; Milone M; Selcen D; Shen XM; Engel AG; Liewluck T Neurology; 2018 Nov; 91(19):e1770-e1777. PubMed ID: 30291185 [TBL] [Abstract][Full Text] [Related]